According to a study by the Institute for Experimental Pediatric Endocrinology of the Charité  – University of Berlin, it is possible.

The researchers have indeed achieved excellent results with patients whose obesity is due to a genetic deficit. The new drug interferes on the satiety mechanisms of the patient suffering from genetic obesity, as it stimulates the production of the so-called “satiety hormone”, leptin, and its subsequent cascade bonds.

In the absence of this hormone, every therapy and effort aimed at reducing body weight are almost useless.

Thanks to the treatment, able to activate the MC4R receptor that regulates the sense of satiety in humans, it can influence energy metabolism and consequent weight loss especially in younger patients.

The team of Dr. Kühnen is studying further to understand why the used peptide is so effective without causing the side effects of similar preparations. In this way, scholars plan to develop a drug that lends itself well to a broader spectrum of patients, even with different cell signaling pathways.

Source:  Charité – Universitätsmedizin Berlin